Recent setbacks in product development at PPL Therapeutics illustrate the economic challenges and regulatory uncertainties that face protein production in GM animals.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk
Scientific Reports Open Access 21 September 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Powell, K. Barnyard biotech—lame duck or golden goose?. Nat Biotechnol 21, 965–967 (2003). https://doi.org/10.1038/nbt0903-965
Issue Date:
DOI: https://doi.org/10.1038/nbt0903-965
This article is cited by
-
Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk
Scientific Reports (2015)
-
Will GM animals follow the GM plant fate?
Transgenic Research (2013)
-
Beer giant blindsides Ventria's pharmacrop
Nature Biotechnology (2005)
